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Simple sphingolipids such as ceramide, sphingosine and sphingosine 1-phosphate are key regulators of diverse cellular functions. Their roles in
the nervous system are supported by extensive evidence derived primarily from studies in cultured cells. More recently animal studies and studies
with human samples have revealed the importance of ceramide and its metabolites in the development and progression of neurodegenerative
disorders. The roles of sphingolipids in neurons and glial cells are complex, cell dependent, and many times contradictory. In this review I will
summarize the effects elicited by ceramide and ceramide metabolites in cells of the nervous system, in particular those effects related to cell
survival and death, emphasizing the molecular mechanisms involved. I also discuss recent evidence for the implication of sphingolipids in the
development and progression of certain dementias.
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In the past decades major findings have emphasized the
significance of sphingolipids as bioactive molecules that control
diverse cellular processes such as proliferation, differentiation,
growth, senescence, migration and apoptosis. Several lines of
evidence, derived mainly from studies using cultured cells,
suggest that sphingolipids are also essential mediators of cell
growth and stress response in the nervous system.
Ceramide is at the centre of sphingolipid metabolism and has
been recognized as a critical second messenger [1]. Ceramide
accumulation is a common cellular response to various stimuli
such as cytokines, ionizing radiation, heat shock, chemother-
apeutic agents, exposure to receptor-specific ligands (TNFα,
Fas ligand, 1,25-dihydroxyvitamin D3), and environmental
factors such as stress, hypoxia/reperfusion, etc.
This review focuses on the role of ceramide and its immediate
metabolites in the regulation of neuronal functions, particularly
survival, death and neurite extension. I also discuss the evidence
directly implicating these sphingolipids in some neurodegen-
erative diseases and other disorders of the nervous system. A
brief introduction of ceramide synthesis and metabolism is
presented although a more detailed discussion is provided by
other reviews in this issue.
2. Ceramide metabolism
Ceramides are cellular precursors of more complex sphin-
golipids namely phosphosphingolipids, glucosphingolipids and
galactosphingolipids. With exception of epidermis where
ceramides form a barrier for water loss [3], most cells contain
very low levels of ceramides under resting conditions. Our
observations however indicate that ceramide mass in sympa-
thetic neurons is exceptionally high [2], as it is in cerebellar
granule cells (CGC) [4,5]. The implications of high levels of
ceramide in neurons are unknown; but neuronal ceramide levels
are still susceptible to augment. Numerous cellular stimuli
induce transient, or sustained increase in ceramide with variable
kinetics. Ceramide levels can reach up to 10 mol% of the totalphospholipids [6] emphasizing the bioactive role of ceramide as
a signaling molecule. Furthermore, since the formation of
ceramide upon stimulation occurs in restricted cellular sites, the
local concentration of ceramide could reach and exceed 25 mol
% [7].
Ceramide is produced de novo, or by hydrolysis of
sphingomyelin (SM) (Fig. 1). The pool of ceramide generated
from the agonist-induced activation of sphingomyelinases
(SMases) has long been involved in the signaling functions of
ceramide. This pathway provides rapid increase of cellular
ceramide levels in response to diverse stimuli. Comprehensive
and extensive reviews of the different SMases and their role in
cell signaling have been published [12,14–16]. The role of
different SMases in the generation of ceramide in cells of neural
origin is discussed below. On the other hand, ceramide
generated from the de novo pathway has been recognized
much later as a second messenger [8–11]. The discovery that
many enzymes involved in the metabolism of sphingolipids are
regulated in response to cellular stimuli has led to the concept of
integrative signaling to explain the contribution of sphingolipid
metabolic pathways in cell regulation [12].
Breakdown of ceramide occurs by the action of ceramidases
(Fig. 1) [17,18]. Interestingly, some ceramidases can catalyze
the reverse reaction and function as a ceramide synthase [19],
therefore they can potentially increase ceramide concentration.
Sphingosine (SPh) is converted to sphingosine 1-phosphate
(S1P) by a family of sphingosine kinases (SPhKs), which are
activated in response to stimulation by diverse agonists (see
[20–22] for review). S1P is itself a very important bioactive
lipid, implicated in several biological processes, often with
effects opposed to those of ceramide.
3. Origin of ceramide in neurons and glia
The involvement of the de novo or the SM breakdown
pathway for ceramide generation in cells from the nervous
system depends both on the stimulus and the cell type. The use
of specific enzyme inhibitors (Fig. 1) has proven very helpful to
discriminate between the two pathways of ceramide production.
Fig. 1. Ceramide synthesis and metabolism. The scheme represents the reactions that take place in ceramide synthesis and ceramide conversion into main metabolites.
The enzymes involved and some of the identified inhibitors are also depicted.
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ceramide accumulation, hence it influences the direct targets
acting downstream of ceramide.
3.1. De novo ceramide synthesis
If de novo synthesis provides the bioactive pool of ceramide,
inhibition of this pathway should block ceramide actions. The
enzymes most targeted for inhibition are SPT and ceramide
synthase (Fig. 1). Several inhibitors of SPT are available namely
myriocin [23], cycloserine [24], β-chloroalanine [25], and
others [24,26,27]. In addition, the inhibitor of ceramide
synthesis fumonisin B1 (FB1) [13,28] has been extensively
used.
Treatment with FB1 inhibits the generation of ceramide and
apoptosis induced by suramine in sensory neurons [29]. Likewise
ceramide elevation and apoptosis induced by retinoic acid (RA) in
PCC7-Mzl cells are blocked by treatment with FB1 but not by
inhibition of SMase activity, suggesting that the pool of ceramide
originates from the de novo synthesis [30].
3.2. Sphingomyelin hydrolysis in neuronal cells
Apoptotic and other stress stimuli usually activate the Mg2+-
dependent neutral SMase (N-SMase) and the lysosomal acidic
SMase (A-SMase). The importance of this mechanism for
ceramide generation in the nervous system was underscored by
the discovery of the activation of SMase upon ligand binding to
the neurotrophin receptor p75 (p75NTR) (see below).3.2.1. Neutral sphingomyelinases
Mammalian Mg2+-dependent N-SMases are membrane
proteins [16] especially enriched in neural tissues [31], and in
cells of neuronal origin [32,33]. During the first 2 weeks of the
neonatal period in the ontogenesis of rat brain the specific
activity of N-SMase rapidly increases in parallel with neuronal
maturation [34], suggesting that ceramide generated from SM
by N-SMase may contribute to normal neuronal survival,
growth and maturation of the CNS. Although the physiological
role of ceramide in brain development remains undefined,
mounting evidence from studies in neuronal and glial cells
indicate that ceramide generated by N-SMase acts as second
messenger in numerous cellular processes.
Activation of N-SMase is responsible for generation of a
pool of ceramide that mediates diverse neuronal responses
ranging from neurite outgrowth and apoptosis in hippocampal
neurons [35,36] to death elicited by the Human Immunodefi-
ciency Virus 1 (HIV) glycoprotein gp120 [37]. In addition,
studies in human neurons [38], oligodendrocytes [39] and brain
sections [40] provided direct demonstration that the amyloid
peptide (Aβ) that accumulates in Alzheimer's disease (AD)
causes N-SMase activation and ceramide accumulation.
A drop in the levels of the major antioxidant glutathione
(GSH) causes activation of at least one type of Mg2+-dependent
N-SMase, and leads to rapid increase in cellular ceramide levels
[41]. The critical role of GSH depletion and N-SMase activation
in cell death has been originally demonstrated by Hannun's
group in human leukemia cells [42] and was later extended to
cells of the nervous system or neuronal models. Cytokine
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term production of oxidants, which transiently deplete GSH
leading to ceramide accumulation and oligodendrocyte apop-
tosis [43]. Likewise, a truncated version of Aβ (Aβ25–35)
induces cell death by causing GSH depletion and activating the
N-SMase pathway in oligodendrocytes [44] and in C6 glioma
cells [45]. In addition, in naïve and differentiated PC12 cells
hypoxia induces N-SMase activation, which is inhibited by
GSH [46]. Supporting the role of GSH in the regulation of
ceramide generation and apoptosis in the nervous system, brain
from patients with multiple sclerosis and X-adrenoleukodystro-
phy showed DNA fragmentation and contained lower levels of
GSH and higher levels of ceramide compared to their aged-
matched controls [43].
3.2.2. Acid sphingomyelinases
The main localization of A-SMase is in the acidic
environment of lysosomes, although a secretory form of A-
SMase exists (for details refer to [14,16]). Mice defective in A-
SMase show selective degeneration of Purkinje cells and loss of
the cerebellar motor coordination system at an early age [47]
suggesting a role for SM metabolism in neuronal survival, and
highlighting the selectivity among neuronal types. The
differential subcellular localization of A- and N-SMase and
the restricted movement of ceramide among intracellular
compartments [48] determine the molecular targets that mediate
ceramide actions and cellular fate. In neurons, compartmenta-
lization is even more pronounced due to their polarized structure
and to the enrichment of acidic endosomes or lysosomes in the
cell bodies. In fact, we have demonstrated that distal axons are
rich in N-SMase activity but contain almost no A-SMase
activity, which is concentrated in cell bodies/proximal axons
[49]. Consequently, in sympathetic neurons the axonal pool of
ceramide, responsible for the inhibition of axonal growth, must
be generated by a N-SMase. On the other hand, some evidence
exists for the involvement of A-SMase in ceramide generation
in other systems such as PC12 cells [50] and SK-N-BE
neuroblastoma cells [51]. The preference of neurons versus cell
lines for signaling through N-SMase has been related to the lack
of functioning cell cycle and proliferation characteristic of
postmitotic neurons [36].
3.3. Mixed mechanisms in ceramide generation
A contribution of both pathways in the generation of
bioactive ceramide has been found in some cell systems. In
neuroblastoma Neuro2a cells, ceramide generated in response
to RA treatment derives from the de novo pathway (possibly by
activation of SPT) as well as from activation of N-SMase [4].
Likewise, generation of ceramide from the de novo pathway
and from SM protect from the cell death that naturally occurs in
cultures of cerebellar Purkinje neurons [52].
3.4. Role of p75NTR in ceramide generation
The discovery that neurotrophins binding to the p75NTR
stimulate SM hydrolysis with simultaneous elevation ofceramide [53,54] highlighted the importance of ceramide in
the regulation of death and survival in the nervous system.
Neurotrophins bind to a member of the Trk family of receptors
in addition to the p75NTR. All neurotrophins bind to p75NTR
with similar affinity, however their affinity to the Trk receptors
is more discriminative such that nerve growth factor (NGF)
binds TrkA, brain-derived neurotrophic factor (BDNF) binds
TrkB and NT3 binds preferentially TrkC but also TrkA but with
much less affinity than NGF [55]. Activation of p75NTR leads to
accumulation of ceramide from SM breakdown [54]. A direct
correlation between the levels of p75NTR expression and the
levels of ceramide has been reported for neuroblastoma cells
[56] and hippocampal neurons [36]. In this last neuronal type
only when p75NTR is expressed at high levels, ceramide-
mediated apoptosis occurs. In addition, a cross-talk between Trk
and p75NTR signaling pathways exists so that simultaneous
binding of neurotrophins to a member of the Trk family and
p75NTR blocks the ability of p75NTR to activate SMase [53]. In
PC12 cells the inhibitory crosstalk between Trk A and p75NTR-
dependent SM breakdown requires phosphatidylinositide-3-
kinase (PI3K) activation, and localizes to caveolae-related
domains [50]. In neuroblastoma cells the negative regulation
between TrkA and p75 is also mediated by PI3K, and involves
protein kinase C (PKC) activation [57].
In sympathetic neurons, which express TrkA and p75NTR we
found that, in addition to the negative cross-talk between TrkA
and p75NTR, there is a dramatic down-regulation of p75NTR
expression when TrkA is not active, which also limits ceramide
production [2]. Therefore, in the absence of TrkA activation
elevation of ceramide is limited, transient and insufficient to
perform the main function of ceramide in sympathetic neurons,
which is survival. The transient pool of ceramide generated from
SM might, however, mediate other short-term cellular effects.
In cultured embryonic hippocampal neurons, which
express TrkB and TrkC but not TrkA generation of an active
pool of ceramide from SM by the action of a N-SMase has
been demonstrated upon treatment with NGF [35,36]. Impor-
tantly, this pool of ceramide is critical to promote neurite
outgrowth or cell death, depending on the age of the neuronal
cultures [35,36]. In cerebellar neurons, NGF-induced activation
of N-SMase through p75NTR generates the pool of ceramide that
mediates glutamate release [58].
In other cases ceramide generated from SM hydrolysis
activated by p75NTR has been involved in cellular process
without sufficient direct evidence. In subplate neurons, ceramide
protects against apoptosis. Although a role for ceramide in
survival is supported by the decrease in neuronal survival that
takes place upon inhibition of de novo ceramide synthesis, direct
indication of SMase activation downstream p75NTR is missing
[59]. Moreover, since subplate neurons express TrkB and
p75NTR but not TrkA, the SMase pathway would likely be
activated by NGF, not by BDNF as the authors propose [59]. A
very similar scenario was reported in subventricular zone-
derived interneurons. Based on the evidence that the ceramide
synthesis inhibitor myriocin caused a decrease in dendrite
development it was suggested that the p75NTR/ ceramide
signaling pathway plays a role in dendritogenesis; however no
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notion of negative cross-talk between Trk and p75NTR, BDNF
induced more pronounced activation of dendritogenesis than
NGF although these cells express TrkB but not TrkA [60].
In conclusion, activation of SMase by p75NTR represents a
major pathway of ceramide generation in cells of the nervous
system, however a very rigorous examination of the origin of
bioactive ceramide must be performed before assigning a
central role to this pathway.
4. Bioactive sphingolipids: ceramide or its metabolites?
Like ceramide, the ceramide metabolites SPh and S1P
induce cell proliferation, differentiation and survival in
several non-neuronal as well as neuronal systems, some of
which are discussed below. In many cases the cellular
responses to ceramide and its metabolites are different.
Ceramide, but not SPh or S1P protects spinal motoneurons
from apoptosis [61]. In hippocampal neurons exogenous
ceramide but not SPh or S1P promotes survival at low
concentration although all three sphingolipids trigger cell
death at concentrations higher than 5 micromolar [62].
Ceramide can be rapidly converted to Sph and S1P (Fig. 1),
hence it is important to understand whether it is ceramide or
a metabolite, which exert the cellular effect.
Ceramide provided to sensory neurons protects from
apoptosis, however the actual lipid mediator seems to be SPh
or S1P since in the presence of the ceramidase inhibitor N-
oleoyl-ethanolamine (NOE), ceramide induces apoptosis [63].
Likewise, in dopaminergic neurons inhibition of the conversion
of ceramide into S1P by N-N′-dimethyl sphingosine (DMS)
blocks the protection against apoptosis [64].
In other systems it is ceramide and not a metabolite,
which has the cellular effect. NGF-induced apoptosis in
hippocampal neurons is enhanced by treatment with the
ceramidase inhibitor D-e-MAPP and, in the absence of NGF,
increasing concentrations of D-e-MAPP results in ceramide
increase and apoptosis indicating the involvement of
ceramide itself, and not a downstream metabolite in inducing
cell death [36]. Likewise we demonstrated that the cerami-
dase inhibitor NOE and the SPhK inhibitor DMS consistently
increase ceramide-induced neuroprotection in sympathetic
neurons and they are able to reduce apoptosis in the absence
of exogenous ceramide. In addition, SPh and S1P are unable
to protect from apoptosis neither they induced apoptosis of
sympathetic neurons [2]. Others examples in which inhibition
of exogenous ceramidase mimic and/or enhances ceramide
effects are the induction of apoptosis by RA in neural stem
cells [30], the apoptosis of oligodendrocytes induced by Aβ
[44] and the induction of apoptosis in SH-SY5Y neuroblas-
toma cells by ceramide [65].
5. Ceramide and its metabolites in survival and apoptosis of
neurons and glia
Neuronal survival is essential for the maintenance of the
neuronal circuits that secure the proper functioning of thenervous system in the adult. However, it is well established that
apoptosis is a normal feature in the development of the
mammalian nervous system. During development neurons
compete for limiting amounts of neurotrophins and approxi-
mately half of the neurons originally present in many parts of the
central nervous system (CNS) and peripheral nervous system
(PNS) undergo apoptosis. This massive loss of neurons is an
important adaptive mechanism for establishing neuronal
populations of the correct size and to guarantee the elimination
of neurons that contact inappropriate targets [66,67]. Extensive
apoptosis also occurs in glial cells during development and, at
least for oligodendrocytes, a “competition for neurotrophin”-like
mechanism has also been recognized [68]. Ultimately, the
survival of neurons and glia depends on the balance of the
actions of several factors and signals from neighboring cells. In
addition to the death of postmitotic neurons, apoptosis also takes
place in the proliferative zones of the brain both embryonically
and postnatally. These are naïve cells that have not extended
processes, and therefore a target-dependent mechanism cannot
account for their death; instead apoptosis seems to be temporally
and spatially coordinated with neuronal differentiation [69].
Although apoptosis is essential for tissue remodeling during
development of the nervous system, inappropriate activation of
apoptosis may contribute to neuronal loss in Alzheimer's and
Parkinson's disease and other neurological disorders [70].
Sphingolipids, in particular ceramide, have demonstrated to
regulate apoptosis, survival and differentiation in cells of the
nervous system as well as in cell lines used as neuronal and glial
models. Many neuronal models have been used to understand
the molecular events involved in the regulation of neuronal
apoptosis or survival by sphingolipids. Although these models
offer a simple approach to obtain information of possible
molecular mechanisms operating in a particular cellular process,
the extrapolation to the physiological situation in vivo must be
done with great caution as has been recently highlighted [71].
The role of ceramide as a regulator of neuronal apoptosis is
complex since ceramide induces or protects from apoptosis
depending on the experimental model considered. The
determinant factor in the final outcome of ceramide actions in
neurons is unknown. Some factors including the cellular type,
the stage of cell development, the concentrations of ceramide
used and the subcellular location of ceramide accumulation
have been discussed [72]. The localization of neurons to the
PNS or CNS does not seem to be crucial, neither is the
localization of neurons to a specific area within the brain.
Moreover, the mechanisms activated downstream of sphingo-
lipid accumulation are also cell type-specific. A good example
is the regulation of the signaling protein Akt. Our work
demonstrated that in sympathetic neurons ceramide causes Akt
activation [2], however in PC 12 cells (a model for sympathetic
neurons) ceramide induces Akt dephosphorylation and inacti-
vation [73]. In view of the cell-type specificity of the effects of
sphingolipids I have decided to present the evidence available
on the role of ceramide and ceramide metabolites on specific
neuronal and glial types. In addition we present a table
summarizing the cellular effects of ceramide and S1P in cells
of neural origin (Table 1).
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The rat pheocromocytoma cell line PC12 represents the most
widely used system to study the regulatory mechanisms of
neuronal survival and apoptosis. PC12 cells have been used as
models for sympathetic neurons since they differentiate
extending neurites when provided with NGF [74,75], as well
as models for dopaminergic neurons since they synthesize and
take up dopamine [76]. Furthermore, many studies directed to
understand cellular death after hypoxia, have been performed in
this model system.
Extensive evidence supports the notion that apoptosis
induced by various insults in PC12 cells, including serum
deprivation [77–79], hypoxia [80], serum and glucose depriva-
tion [81], angiotensin II [82,83] and choline deficiency [84] is
mediated by ceramide. Exogenously added short- and long-
chain ceramides also induce apoptosis of naïve PC12 cells [85]
and apoptosis and neurite retraction in NGF-differentiated PC12
cells [76]. Addition of NGF or other neurotrophic factors at the
time of treatment with short-chain ceramide dramatically
decreases ceramide-induced apoptosis [86].
In many systems the ceramide metabolite S1P triggers
cellular effects opposite to ceramide, which led to the proposal
of the existence of a ceramide-S1P rheostat [87]. In PC12 cells
NGF stimulates the formation of S1P by activating the enzyme
SPhK, in a process that requires activation of the neurotrophin
receptor TrkA [78]. NGF not only regulates SPhK 1 at the
activity level but also increases SPhK 1 gene expression [88].
Accumulation of endogenous S1P secondary to NGF treatment
(as well as addition of exogenous S1P) protects PC12 cells from
apoptosis induced by serum withdrawal or by ceramide [77,78].
This evidence indicates that NGF acts as a regulator of the
intracellular ration of ceramide to S1P in PC12 cells [78]. The
observation that elevation of S1P cellular content is required for
the neurotrophic-like factor prosaposin to prevent staurosporin-
and ceramide-induced cell death [89] emphasizes the signifi-
cance of the intracellular balance between ceramide and S1P in
this cell type.
In contradiction with the notion that S1P is antiapoptotic,
recent work indicated that exogenous S1P causes apoptosis of
PC12 cells, although at concentrations higher than those used
by Spiegel's group [90]. Differential expression of S1P
receptors in PC12 cells might provide some insights for the
contradictory findings, although it has been demonstrated that G
protein-coupled receptor signaling does not mediate the
antiapoptotic effect of S1P in PC12 [77]. By contrast, the
effect of S1P on neurite outgrowth depends on S1P receptors.
Conflicting evidence indicates that exogenous S1P induces
rapid neurite retraction in differentiated PC12 [91] but enhances
NGF-induced neuritogenesis in naïve PC 12 cells [78]. NGF
causes translocation of SPhK from the cytoplasm to the plasma
membrane and triggers preferential activation and internaliza-
tion of the S1P receptor S1P1 over S1P2 [92]. S1P1 activation is
linked to neurite extension while activation of S1P2 causes
neurite retraction.
Several molecular mechanisms activated by ceramide and
S1P in PC12 cells have been reported. Ceramide leads to veryearly increase of mitochondrial and cytosolic Ca2+ concentration
[93], to the formation of reactive oxygen species (ROS) of
mitochondrial origin followed by the translocation of NFκB to
the nucleus [76,79], and to the activation of c-Jun amino-
terminal kinase (JNK) [86] and caspases [85]. In spite of initial
indications that the production of ROS is necessary for
ceramide-induced apoptosis in PC12 cells to occur [76], later
evidence suggests that the increase of cytosolic [Ca2+] and the
production of ROS are not responsible for ceramide-induced
apoptosis, but the increase in mitochondrial [Ca2+] is required
[94]. This increase in mitochondrial [Ca2+] does not result from
entry of extracellular or cytosolic Ca2+ but might be mediated by
Ca2+ transfer from the ER to the mitochondria since closer
interactions between these two organelles exist in ceramide-
treated PC12 cells [93], as well as in mesencephalic neurons (see
below) [95]. Ceramide-induced calcium transfer from ER to
mitochondria is regulated by at least two concerted mechanisms.
Ceramide induces cyclin-dependent kinase 5 (CDK5) activation,
which mediates tau phosphorylation and dissociation from
microtubules, facilitating organelle movement and redistribution
[95]. However, CDK5 itself is not responsible for Ca2+ transfer,
which requires the activation of caspase 8 and the cleavage of the
caspase substrate Bid to cause cytochrome c release and
apoptosis [95,96]. Supporting the role of caspase 8, over-
expression of the caspase 8 inhibitor CrmA reduces TNFα-
induced ceramide increase and apoptosis of PC12 cells [97].
Whether ceramide directly activates caspase 8 in neuronal cells
is unknown but in Tcell lines the sequence of events triggered by
ceramide is caspase-2 and caspase-8 activation; Bid cleavage
and translocation; mitochondrial damage; caspase-9 and-3
activation, and cell apoptosis [98]. Caspase 3 activation takes
place in ceramide-treated PC12 cells, but the evidence suggests
that caspase3 does not mediate apoptosis [96].
The significance of ceramide-induced NFκB translocation to
the nucleus [76,79] is uncertain since there is strong indication
that NFκB activation contributes to the survival (not death) of
PC12 cells and sympathetic neurons [99–101], and that NFκB
plays a physiological role in maintaining survival of CNS
neurons [102]. The survival of NGF-dependent PC12 cells is
determined by the functional interplay between NFκB and c-Jun
that compete for binding to the transcriptional coactivator p300/
CBP [100]. c-Jun expression is regulated by several signaling
pathways. Among them, the concerted activation of ERK 1/2
and JNK leads to c-Jun phosphorylation and increase of its own
expression, which is important for neuritogenesis in PC12 cells
[103]. NGF and other neurotrophic factors that block ceramide-
induced apoptosis in PC12 cells do not alter JNK activity and
moreover, they are efficient when provided after JNK activation
suggesting that neurotrophic factors act downstream of JNK
[86]. On the other hand, endogenous S1P promotes survival by
inhibiting JNK [77]. However both S1P and NGF act
independently of Akt and ERK 1/2 [77,86] indicating that the
promotion of survival is due to inhibition of pro-apoptotic
events rather than activation of classical pro-survival signals.
Similarly, Salinas and co-workers have proposed that ceramide-
induced apoptosis in PC12 cells is not due to activation of a pro-
apoptotic pathway but depends on inhibition of the Akt survival
Table 1
Effect of ceramide and ceramide metabolites in neurons and glial cells
Cellular effect Mediator Cell type Inducer Mechanism Reference
Apoptosis Ceramide PC12 cells C2-cer JNK [85,86]
C2-cer NFkB/ROS [76]
C2-cer, C8-cer DAPK [106]
C2-cer CDK5; tau dephosphorylation; Bid [95]
Serum deprivation [77,78]
Serum/glucose
deprivation JNK [81]
NGF/cAMP withdrawal NFkB [79]
TNFα Caspase 8 [97]
Angiotensin II [82,83]
Choline deficiency Caspase 3 [84]
S1P S1P p38 [90]
Ceramide Sensory neurons Ceramide+NOE [63]
Suramin NFkB; reentry to cell cycle [29]
Ceramide Hippocampal neurons C2-ceramide > 5
micromolar [62]
NGF JNK [36]
C2-ceramide; SMase DAPK [114]
S1P S1P [62,123]
Ceramide Cerebellar granule cells C2-ceramide;
SMase; etoposide [5,128,131,130]
C2-ceramide;
serum deprivation JNK; Bax; Caspase 9; caspase 3
[129,134]
C2-ceramide Akt and GSK3 dephosphorylation [132]
Ceramide Cortical neurons C2-ceramide;
serum withdrawal JNK/c-Jun; p38 [142,146]
C2-ceramide; SMase [5]
C2-ceramide Caspase 9; caspase 3 [143]
C2-ceramide; PDMP p38; Akt inactivation;
BAD; GSK3; cas 3 [144,147]
Ceramide Mesencephalic neurons C2-ceramide > 1
micromolar ROS; NFkB [148]
C2-ceramide CDK5; tau dephosphorylation, Bid [149]
C2-ceramide [95]
Ceramide Motoneurons C6-ceramide > 5
micromolar Bax; [Ca2+]int increase; caspase 3 [150]
Ceramide HN9, 10e Serum deprivation;
C2-ceramide [152,153]
Ceramide PCC7-Mz1 cells RA [30]
Ceramide Oligodendrocytes NGF JNK [158]
Aβ25-35 JNK; DP5 [163,44]
Ceramide Astrocytes Palmitic acid Raf-1/Erk [165]
C2-ceramide Cytochrome c release [167]
Survival S1P PC12 cells NGF SPhK activation/JNK inhibition [78]
Ceramide Sympathetic
neurons
C6-ceramide [117]
C6-ceramide Inhibition of ROS and C-Jun [118]
C6-ceramide; PPMP TrkA and PP1 activation [2,119]
S1P Sensory neurons Ceramide [63]
Ceramide Immature
hippocampal neuron C6-ceramide < 5 micromolar [62]
Ceramide? Purkinje cells C6-ceramide; SM, SPh, S1P [141]
S1P Mesencephalic neurons C2-ceramide < 1 micromolar [64]
Ceramide Motoneurons SMase, low C6-ceramide Inhibition of oxidative stress [150]
S1P Oligodendrocytes NT3 SPhK activation and
translocation
[164]
Differentiation/
neurite extension
S1P PC12 NGF SphK/S1P, activation [5,77]
S1P NGF-primed
sensory neurons S1P SphK/S1P, activation [92]
Ceramide Hippocampal neurons C6-ceramide; SMase [121]
Hippocampal neurons 1DIV NGF [35,36]
(continued on next page)
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Table 1 (continued)
Cellular effect Mediator Cell type Inducer Mechanism Reference
Ceramide Motoneurons SMase; low C6-ceramide [150]
Ceramide Neuro 2A C2-ceramide; SPh [4]
Neurite retraction/
Inhibition
of axonal growth
Ceramide PC12 cells C2-cer [76]
S1P S1P [91]
Ceramide Sympathetic neurons C6-ceramide; SMase; PPMP Inhibition of NGF uptake [49,120]
Ceramide Cerebellar granule cells C2-ceramide PP2A, tau dephosphorylation [135]
Ceramide Cortical neurons C2-ceramide [142,146]
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treatment with ceramide for a short time blocks NGF-induced
Akt activation by a mechanism that might involve activation of
the serine/threonine protein phosphatase 2 (PP2A) a known
target of ceramide. The likelihood of such a mechanism in
neurons that respond to NGF should be carefully considered in
view of the evidence of ceramide activation of the NGF receptor
TrkA. Although pre-treatment of PC12 cells with ceramide for
short periods of time as those used in Salina's studies might not
have affected TrkA, it has been demonstrated that longer
ceramide exposure dramatically increases NGF-induced TrkA
activation and even causes TrkA phosphorylation in the absence
of NGF in PC12 cells [104]. Our group demonstrated similar
NGF-independent activation of TrkA by ceramide in sympa-
thetic neurons (see below) [2]. Since Akt phosphorylation
represents one of the main downstream effects of TrkA
activation [55,105] the enhancement of TrkA signaling by
ceramide will counteract ceramide-induced Akt dephosphor-
ylation and the final cellular outcome will depend on the
balance of both signals.
Also required for ceramide-induced apoptosis of PC12 cells
is the activation of the Ca2+/calmodulin-regulated, serine/
threonine kinase Death-Associated Protein-kinase (DAPK)
[106]. DAPK is an actin filament-associated pro-apoptotic
protein [107] with undeniable relevance in the nervous system.
In rat brain, DAPK mRNA is present from embryonic day 13
(E13) throughout the proliferative and postmitotic regions
within the cerebral cortex, hippocampus and cerebellar Purkinje
cells; after birth DAPK expression is restricted mainly to the
hippocampus [108,109]. DAPK has been implicated in
ischemic injury [110,111] and in neuronal death in epilepsy
[112,113]. The involvement of DAPK in ceramide-induced
apoptosis in cultured primary neurons has also been reported
(see below) [114]. In non-neuronal cells the mechanism
underlying the apoptotic effect of DAPK involves inhibition
of integrin-mediated cell adhesion and extracellular matrix
signal transduction [115]. Although it seems unlikely that this
mechanism would be restricted to a particular set of cells, direct
demonstration in neurons is still pending. Other target identified
for DAPK in neurons is the CaM-regulated protein kinase
kinase (CaMKK), which has been proposed as a therapeutic
target in neurodegenerative diseases [116].
5.2. Sympathetic neurons
Sympathetic neurons represent the prototype neurons of the
PNS and have been used extensively to study the moleculardetails of neuronal apoptosis since in culture they die in a
synchronous manner when deprived of NGF. It has been long
known that upon NGF withdrawal, addition of short-chain
ceramide to the culture medium prevents programmed cell
death [117] but only in more recent years the mechanisms
behind the survival effect of ceramide have been deciphered.
Our laboratory demonstrated that treatment of sympathetic
neurons with C6-ceramide results in increase of endogenous
long-chain ceramides and that ceramide generated from the “de
novo” pathway is as effective as C6-ceramide in inhibiting
apoptosis [2]. The generation of endogenous ceramides after
treatment of cells with the short-chain ceramide analogues C2-
and C6-ceramide had been described previously for fibroblasts
[118] and A549 human lung carcinoma cell line [119]. A
proposed mechanism for the neuroprotective action of ceramide
in sympathetic neurons includes the blockade of oxidative stress
and c-jun induction that takes place early after NGF deprivation
[120]. However, this cannot be the sole mechanism since C6-
ceramide is able to prevent apoptosis when provided to the
neurons after ROS have been produced and c-jun has been
activated [2]. We found that C6-Cer activates the neurotrophin
receptor TrkA and its downstream effector Akt [2]. As
mentioned above, activation of TrkA by ceramide had been
previously demonstrated in PC12 cells [104]. However, since
ceramide causes apoptosis in PC12 cells [77,78,85] the
relevance for ceramide-induced TrkA in this neuron-like system
is unknown. Our most recent work indicates that C6-ceramide-
induced TrkA activation in the absence of NGF takes place in
sphingolipid and cholesterol-rich microdomains (lipid rafts).
C6-ceramide accumulates in lipid rafts, where TrkA resides,
likely creating “ceramide-patches” that allow for increase local
density of TrkA leading to dimerization and autophosphory-
lation1. TrkA activation, however, does not represent the only
pro-survival mechanism elicited by ceramide. We demonstrated
that protein phosphatase 1 (PP1) is activated in ceramide-treated
sympathetic neurons and is required for ceramide-induced
protection against apoptosis [121]. Although the direct targets
of ceramide-activated PP1 in sympathetic neurons have not
been completely identified, we showed that ceramide is able to
prevent the hyperphosphorylation of retinoblastoma gene
product (pRb) that takes place upon NGF deprivation, by a
mechanism dependent on PP-1 activation. We proposed that
reduced phosphorylation of pRb will abort the attempt to re-
enter the cell cycle after NGF withdrawal, which in neurons can
2003E.I. Posse de Chaves / Biochimica et Biophysica Acta 1758 (2006) 1995–2015lead to apoptosis [121]. It is important to highlight that contrary
to evidence from PC12 cells, Akt, which is a known substrate
of serine/threonine protein phosphatases is not dephosphory-
lated but instead Akt phosphorylation is increased in ceramide-
treated sympathetic neurons. As discussed above, this might be
explained by the balance of signals generated downstream of
TrkA activation. An alternative explanation is that Akt might
be a better substrate for PP2A than for PP1 since we have
found that PP2A activity is very low in sympathetic neurons
[121].
With respect to the role of ceramide in axonal growth and
regeneration of sympathetic neurons we have shown that C6-
ceramide, bacterial SMase and ceramide accumulated intracel-
lularly by inhibition of GlcCer synthesis, inhibit axonal growth
of sympathetic neurons independently of cell death [49,122].
The ceramide pool that inhibits axonal growth is generated from
SM in distal axons, but not in cell bodies. Analysis of
endogenous SMase activities demonstrated that distal axons
are rich in N-SMase activity but contain almost no A-SMase,
which is concentrated in cell bodies/proximal axons. This is
consistent with the notion that generation of ceramide from SM
by N-SMAse in axons inhibits axonal growth [49]. The
mechanism responsible for axonal growth inhibition involves
reduction of NGF uptake and decrease of ERK activation in
ceramide-treated neurons [2,49].
5.3. DRG/sensory neurons
Sensory neurons resemble sympathetic neurons in that they
strongly depend on neurotrophins for survival and undergo
apoptosis when deprived of trophic support. Neurons from the
dorsal root ganglia (DRG) represent a more heterogeneous
population with approximately one third of the neurons
responding to NGF. When exposed to exogenous natural
ceramides sensory neuron survival rate is increased both in the
absence or presence of NGF [63]. Thus, sensory neurons
respond to ceramide like sympathetic neurons, however, the
actual lipid mediator in sensory neuron survival is not ceramide
but a metabolite, possibly SPh or S1P. The ceramidase inhibitor
NOE not only blocks survival but induces apoptosis, indicating
that ceramide is indeed proapoptotic in DRG neurons [63].
Other work supporting the proapoptotic role of ceramide in
DRG neurons demonstrated that treatment with the drug
suramin, cause increase of endogenous ceramide in sensory
neurons and leads to apoptosis [29]. The mechanism of
ceramide-induced apoptosis involves translocation of NFκB
to the nucleus and stimulation to re-entry the cell cycle as
indicated by the increase in cyclin D1 [29].
NGF regulates neurite outgrowth and elongation in a
subpopulation of sensory neurons, and this regulation is altered
by S1P. If S1P is provided to DRG neurons together with NGF
at the time of plating, it blocks NGF-induced neurite
outgrowth; but S1P enhances NGF-induced neurite outgrowth
when given after a few hours of exposure to NGF [92]. The
differences in the effects elicited by S1P are explained by NGF-
mediated regulation of S1P receptors. NGF causes an increase
in the expression of S1P1 and a decrease in the expression ofS1P2, which promotes and inhibits neurite growth respectively
[92].
5.4. Hippocampal neurons
Hippocampal neurons death is responsible for memory
dysfunction and is characteristic of some neurodegenerative
diseases such as AD. Several lines of evidence have recognized
ceramide and its metabolites as important second messengers in
hippocampal neuron biology. The effects of ceramide on
hippocampal neuron survival depend on the developmental
neuronal stage and the concentration of ceramide used. At
concentrations below 5 micromolar exogenous ceramide either
does not affect survival during the first day in culture [123] or
increases cell viability [62]. In addition, ceramide concentra-
tions lower than 1 micromolar protect hippocampal neurons
from several insults such as excitotoxicity, FeSO4 and amyloid
β-peptide (Aβ) [124]. At concentrations over 5 micromolar
exogenous ceramide given to immature hippocampal neurons
causes apoptosis [62,123]. In mature hippocampal neurons
(after 6–7 DIV) even low concentrations of ceramide cause cell
death [62]. Similarly, treatment with NGF during the first day in
culture does not compromise neuronal viability but after 2 DIV
NGF causes apoptosis [36]. This switch in the response to NGF
correlates with the increase in expression of p75NTR and the
increase in ceramide generation [36]. Some studies indicate that
the mechanism of NGF-induced apoptosis might require
mitogen-activated protein kinase (MAPK) activation, particu-
larly JNK, although the intermediates between ceramide and
JNK and the mechanisms downstream of JNK have not been
identified [36]. Activation of the MAPK/JNK pathway in
ceramide-treated hippocampal neurons, was not found in other
studies [62], however further differences such as the lack of
expression of p75NTR also existed in these, compared with
Futerman's studies and might be explained by differences in the
neuronal cultures. More recently, a pivotal role for DAPK in
ceramide-induced apoptosis of hippocampal neurons was
discovered [114]. Expression of DAPK is increased by
ceramide in rat hippocampal neurons and neurons isolated
from DAPK null mice are significantly more resistant to
undergo apoptosis when challenged with ceramide analogs or
high NGF concentrations [114]. Underscoring the physiological
relevance of DAPK in hippocampal neuron apoptosis, DAPK
mRNA expression becomes restricted to the hippocampus after
birth [109].
Contrary to the situation in PC12 cells, in hippocampal
neurons S1P does not have effects opposite to ceramide on
survival. Indeed, at low concentrations exogenous S1P does not
affect neuronal survival; but causes apoptosis at higher doses
[62,125]. S1P-induced apoptosis is blocked by the Ca2+
chelator BAPTA-AM and by protein phosphatase inhibitors,
and involves c-Fos-containing activator protein-1 (AP-1)
complexes as transcription factors [125]. Unfortunately whether
S1P itself or ceramide derived from S1P is responsible for the
apoptosis has not been investigated.
With respect to the role of sphingolipids in hippocampal
neurite outgrowth, Futerman's group demonstrated, using the
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axon development, ceramide must be converted to GlCer to
maintain normal growth [123,126]. In addition, the first stage
of differentiation, that is the formation of minor processes
from lamellipodia, is independent of ceramide metabolism
into GlCer and is stimulated by short-chain ceramide analogs
and by generation of endogenous ceramide by SMase [123].
Moreover, ceramide participates in dendritic formation and
elongation [62]. Although these findings are in apparent
contradiction with our data from sympathetic neurons (see
above), our studies were performed after 5–10 DIV and under
our experimental conditions we only examined axonal ex-
tension but we could not evaluate neurite outgrowth, axonal
branching or dendrite extension [122].
As mentioned above, one of the main pathways for ceramide
generation in neurons is triggered by activation of the
neurotrophin receptor p75NTR. Hippocampal neurons express
p75NTR as well as TrkB and TrkC, but the expression of TrkA in
these neurons is negligible at least up to 4 DIV [35,36].
Consequently, NGF is able to activate p75NTR without activating
Trk, and to increase ceramide levels by activation of N-SMase.
This, in turn, leads to significant activation of axonal growth
during the first day in culture [35].
Other important effects of ceramide in hippocampal neurons
include modulation of ion currents, neurotransmitter release and
synaptic transmission [127,128]. These actions of ceramide
have been recently reviewed in detail [129].
5.5. Cerebellar neurons
Significant number of studies addressed the role of ceramide
in apoptosis of neurons of cerebellar origin. Cerebellar granule
cells (CGC) represent the most abundant neurons of the CNS.
Treatment of CGC in culture with exogenous short-chain
ceramides or bacterial SMase causes apoptosis [5,130–133].
Serum/K+ deprivation or exposure of granule cells to the anti-
cancer agent etoposide leads to accumulation of endogenous
ceramide and CGN death [131]. Recent studies have revealed,
at least in part, the mechanisms involved in ceramide-induced
apoptosis of CGCs. Ceramide induces dephosphorylation of
Akt and glycogen synthase kinase-3 (GSK3), possibly through
the activation of a PP2A-like activity [134]. Multiple mechan-
isms might contribute to the promotion of apoptosis by GSK3.
Among them, GSK3 is a natural activator of the mitogen-
activated protein kinase kinase kinase (MEKK), which in turns
triggers the JNK signaling pathway [135]. Consistent with this
possibility, ceramide strongly stimulates JNK phosphorylation
in CGCs [131]. Gene transcription activation downstream of
JNK results in increase of BAX, decrease in mitochondrial
membrane potential, release of cytochrome c from the
mitochondria and activation of caspase-9 and caspase 3 [136].
These findings contradict earlier observations that a caspase 3
inhibitor was unable to block morphological alterations and cell
death triggered by prolonged granule cell exposure to ceramide
[132].
In addition to the activation of apoptosis, C2-cer induces
rapid and transient activation of cell migration and inhibitsneurite outgrowth in immature CGC [137]. These effects have
been attributed to disorganization of the microfilament network
and to decreased phosphorylation of the microtubule-associated
protein tau by a mechanism mediated by caspases and PP2A
[137].
Based on: 1) the effects of ceramide on CGC in culture; 2)
the evidence that mice overexpressing TNF-α present strong
impairment of cerebellum development and 3) the fact that
ceramide mediates many of the cellular effects of TNF-α;
Falluel-Morel and collaborators proposed that ceramide-
induced apoptosis plays a role in cerebellum development
[136,137]. Supporting this notion Sonino and colleagues
demonstrated in cerebellum a progressive increase in ceramide
content in sphingolipid-enriched membrane domains from the
time of neuronal differentiation and neuritogenesis to the latest
stage of development, a time at which massive age-induced
apoptotic death takes place [138].
A second, important neuronal type present in the cerebellum
is Purkinje cells. Cellular levels of ceramide and other
sphingolipids are critical for survival and differentiation of
Purkinje cells. Inhibition of ceramide synthesis and depletion of
sphingolipids result in Purkinje cell apoptosis, which is reverted
by administration of C6-ceramide, SM, SPh or S1P [52]. These
studies in vitro suggest that ceramide and related metabolites
have a protective role against apoptosis in Purkinje cells.
Conflicting with the notion that ceramide is a survival mediator
in Purkinje cells, studies in animals in which the putative
lysosomal ceramidase activator saposin D was deleted, demon-
strated that accumulation of ceramide in the cerebellum is
accompanied by selective degeneration and death of Purkinje
cells [139]. This evidence favors the notion that a metabolite of
ceramide such as S1P is the possible survival mediator in
Purkinje cells. Although the observation that selective degen-
eration of Purkinje cells occurs in ASMase-deficient mice
supports a role of SM-derived ceramide in neuronal survival
[47], these findings could also be explained by decreased
production of S1P. Interestingly, the loss of Purkinje cells in
ASMase-deficient mice does not occur at random but it rather
takes place in a very well-ordered array of stripes in which
Purkinje cells expressing the protein zebrin II are more resistant
to death [140]. Strikingly, the stripped pattern of zebrin II
expression correspond to the expression of SPhK [141].
Neurons expressing SPhK might be able to synthesize more
efficiently S1P from a reduced pool of ceramide, and S1P might
be the true antiapoptotic mediator. Further research should
determine the levels of sphingolipids (ceramide, SM, S1P) in
the surviving Purkinje cells in order to be able to identify the
bona fide survival mechanism. Taking in consideration the high
expression of S1P receptors in cerebellar neurons, particularly
Purkinje cells, and the secretion of S1P by cerebellar neurons
[142] further studies in this area are granted.
With respect to the role of ceramide in Purkinje cell
differentiation, Furuya and colleagues showed that sphingo-
lipid synthesis is required for proper dendrite differentiation
of Purkinje cells in mixed cultures [52,142]. More specifi-
cally, the loss of ceramide and/or SM was identified as
responsible for dendritic abnormalities. Interestingly, CGCs
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sphingolipids.
5.6. Cortical neurons
Cortical neurons respond to cellular ceramide elevation in a
manner similar to CGCs. Treated with C2-cer or exogenous
SMase cultured cortical neurons undergo apoptosis
[2,144,145]. The molecular mechanisms activated by ceramide
in cortical neurons are also very close to those activated in
cerebellar neurons. A rapid dephosphorylation of Akt, likely
mediated by PP2A, takes place in the first hour of ceramide
treatment [146,147]. Akt dephosphorylation is required for
ceramide-induced apoptosis since activation of Akt by insulin
growth factor-1 prevented neuronal death [147]. Akt depho-
sphorylation is followed by dephosphorylation of the proa-
poptotic regulators BAD, Forkhead family transcription factors
and GSK3, which after 2–6h cause mitochondrial depolariza-
tion and permeabilization, and activation of the intrinsic
cascade pathway [146]. Although the targets downstream of
GSK3 have not been directly identified, activation and nuclear
translocation of JNK, activation of p38 and phosphorylation of
c-Jun have been demonstrated in ceramide-treated cortical
neurons [144,148]. The requirement of p38 activation has been
confirmed, however JNK activation upon ceramide treatment
was not found by others [149]. The involvement of ERK in
ceramide-induced death in cortical neurons was also investi-
gated with contradicting conclusions. Two research groups
found that ceramide causes significant decreased of ERK 1/2
phosphorylation [144,149]. However, inhibition of Erk 1/2
phosphorylation by the MEK inhibitor PD98059 in the absence
of ceramide did not cause apoptosis, from which Willaume et
al. concluded that ERK 1/2 are not mediators of cortical
neurons apoptosis [144]. Stoica and colleagues followed a
similar strategy but used the MEK1/2 inhibitor U0126 for co-
treatments with ceramide and found that U0126 is able to
reduce ceramide-induced apoptosis concluding that ERK1/2
are involved in the apoptotic pathway [149]. If the decrease in
Erk 1/2 phosphorylation induced by ceramide is required for
ceramide-induced apoptosis it is very difficult to understand
how an inhibitor that has the same effect than ceramide on Erk
phosphorylation can prevent ceramide-induced cell death.
Extensive evidence indicates that ceramide-induced apopto-
sis of cortical neurons is accompanied by caspase 3 and caspase
9 activation [144–146,149]. Indeed, by using caspase inhibitors
Movsesyan and collaborators demonstrated the requirement of
caspase 3 and caspase 9 but not caspase 8 activation in
ceramide-induced apoptosis of cortical neurons [144]. The
inability of caspase 3 inhibitor to prevent apoptosis of these
neurons in previous work by Willaime et al. might be explained
by the concentration of inhibitor used [144].
With respect to neurite development and extension,
treatment of cortical neurons with ceramide causes rapid
neurite retraction and loss of dendritic MAP2 immunoreactiv-
ity [144,148], however it is unclear if these effects are
secondary to neuronal death or are due to independent actions
of ceramide.5.7. Mesencephalic neurons
Mesencephalic dopaminergic neurons represent the major
cell population that degenerates in patients with Parkinson's
disease (PD). Morphological studies on postmortem brain from
patients with PD indicate that these neurons die by apoptosis.
Almost a decade ago the hypothesis that the SM cycle could
mediate neurodegeneration in PD [76] promoted studies aimed
to understand the role of ceramide in apoptosis of mesence-
phalic neurons. The SM hypothesis of neuronal death was based
on evidence indicating that 1) dopaminergic neurons that
degenerate in PD express TNF-α receptors; 2) TNF-α
immunoreactive glial cells localize in proximity to these
neurons in PD patients and 3) ceramide is an important second
messenger in TNF-α signaling.
Classical experiments using short chain ceramides indicated
that, as in hippocampal neurons, ceramide has dual effects in
cultured mesencephalic neurons, depending on the concentra-
tion. Short-chain ceramide at concentrations less than 1
micromolar protects cultured mesencephalic neurons against
glutamate cytotoxicity by conversion to its metabolite S1P [64].
Over micromolar concentrations exogenous ceramide induces
apoptosis [150]. The apoptotic process involves generation of
ROS and NFkB translocation to the nucleus [151]. As in PC12
cells, ceramide induces an increase in CDK5 activity, which
leads to tau phosphorylation causing the clustering of ER and
mitochondria and enhancing t-Bid-mediated Ca2+ transfer [95].
Tau phosphorylation can be catalyzed by GSK3 as well,
however in contrast to CGC [134] and cortical neurons [144]
ceramide does not activate GSK3 in mesencephalic neurons
[95]. Moreover, although GSK3 is activated in CGCs, tau
phosphorylation is not increased but is reduced in this neuronal
type [137], highlighting once again, the cell specificity in
ceramide effects.
5.8. Motoneurons
The effects of ceramide in embryonic spinal motoneurons
are similar than in hippocampal neurons. Low concentra-
tions of C6-ceramide or treatment with bacterial SMase
prevent the natural death that occurs in vitro and improves
axonal elongation. Conversely, higher C6-ceramide concen-
trations lead motoneurons to apoptosis [152]. Ceramide
prevents motoneuron apoptosis by inhibition of oxidative
stress [61].
5.9. Neuroblastoma cells
Neuroblastoma cells represent good models to study the
role of sphingolipids in neuronal apoptosis in the proliferative
areas of the nervous system. In addition, understanding the
mechanisms that mediate apoptosis in neuroblastoma cells is
important to design strategies for the prevention of apoptosis
in immortalized neuronal stem cells and progenitor cells,
which have therapeutic potential in the treatment of
neurodegenerative disorders. In general, ceramide causes
differentiation and/or apoptosis in neuroblastoma cells,
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ceramide elevation. Some examples follow.
The embryonic hippocampal cell line HN9.10e has been
extensively used as an experimental model for hippocampal
neurons. These cells are a somatic fusion product of
hippocampal neurons from embryonic day 18 C57BL/6 mice
and N18TG2 neuroblastoma cells. They exhibit morphological
and cytoskeletal features which are typical of their neuronal
parent but which are not expressed by the neuroblastoma parent
[153]. Study of apoptosis in undifferentiated HN9.10e provides
information of cellular processes that occurs during embry-
ogenesis. Serum deprivation of undifferentiated HN9.10e cells
causes accumulation of intracellular ceramide and apoptosis.
The apoptotic process is also triggered by short-chain ceramide
analogs [154]. The cell death mechanisms include translocation
of the proapoptotic Bcl-2 family member Bax to the
mitochondria and release of cytochrome cwithout mitochondria
depolarization or swelling [154,155]. A later increase in
intracellular [Ca2+] takes place, however, contrary to the case
of PC12 cells, mitochondrial [Ca2+] does not change. Caspase 3
is activated many hours after cytochrome c release [154].
Recently, it has been reported that the early elevation of
ceramide that follows serum deprivation is the result of the
change in the balance between SMase and SM synthase activity
of nuclear origin [156].
In neuroblastoma neuro 2A cells differentiated with RA there
is a rapid and sustained increase in ceramide and a decrease in
SM [4]. Direct application of natural or short chain ceramides or
SPh also induces neurite differentiation [4], being the effect of
SPh, strictly related to its conversion to ceramide [157].
RA also causes differentiation of PCC7-Mz1 cells into
neurons, astroglial cells and fibroblasts while a fraction of RA-
treated cultures dies by apoptosis. Although RA causes ceramide
elevation, in this case by activation of the enzyme SPT [30],
ceramide does not promote differentiation but induces apoptosis
since treatment with FB1 reduces RA-induced cell death but not
neurite formation [30]. The differential response of PCC7-Mz1
and Neuro2A cells to ceramide-induced differentiation was
interpreted as depending on the degree of commitment that the
cell already has at the time of ceramide increase [30]. While
Neuro2a cells have already committed to a neuronal differentia-
tion, PCC7-Mz1 cells still conserve the potential to differentiate
in all cell types derived from the neuroectoderm.
On the other hand treatment of undifferentiated SK-N-BE
neuroblastoma cells with TNF-α causes ceramide elevation and
increased differentiation, while TNF-α induces apoptosis in
RA-differentiated SK-N-BE cells [51].
Short chain ceramides also induce apoptosis in SH-SY5Y
neuroblastoma cells [65,145], SKN-SH cells [158] and
hypothalamic GT1-7 cells [159], while addition of S1P induces
SH-SY5Y cells proliferation [65].
5.10. Glial cells
5.10.1. Oligodendrocytes
Chao and collaborators demonstrated that ceramide elevation
causes selective apoptosis in mature oligodendrocytes withoutaffecting astrocytes and oligodendrocyte precursors [160,161].
The mechanism of apoptosis involves activation of JNK [160]
and p38α [162]. Ceramide originates from the hydrolysis of SM
that occurs upon binding of NGF to p75NTR expressed in
oligodendrocytes. Retroviral expression of Trk A in mature
oligodendrocytes inhibits NGF-induced p75NTR-dependent
apoptosis, blocks JNK stimulation, and instead, induces ERK
1/2 activation [163]. Interestingly, although under physiological
conditions in vivo oligodendrocytes do not express p75NTR, up-
regulation of p75NTR messenger RNA and protein were
demonstrated in oligodendrocytes and microglia/macrophages
in multiple sclerosis plaques [164], suggesting a role for p75NTR
(and possibly ceramide) in cell death in this disease. Likewise,
ceramide might also play a role in Aß-induced oligodendrocyte
death since inhibition of SMase is able to block the apoptotic
pathway activated by Aß that involves JNK and the proapototic
protein DP5 [44,165]. Direct evidence of ceramide accumula-
tion and/or SMase activation in Aβ-treated oligodendrocytes
however has not yet been presented.
As in other cell types SPh and S1P exert effects different than
ceramide in oligodendrocytes. SPh causes non-apoptotic cell
death and S1P does not affect survival. S1P activates JNK/p38
although it causes activation of Erk 1/2 [162] and is able to
induce phosphorylation of cyclic AMP-response element
binding protein (CREB) downstream of Erk 1/2 [166]. CREB
activation and survival support is also elicited by treatment of
oligodendrocytes with the neurotrophin NT3. The survival
mechanism activated by NT3 is similar to the mechanisms
discussed for PC12 cells treated with NGF; exposure of
oligodendrocytes to NT3 causes translocation of SPhK to the
plasma membrane and SPhK activation with the consequent
increase in S1P [166].
5.10.2. Astrocytes
As mentioned above, some studies indicated that the survival
of astrocytes in a mixed culture with oligodendrocytes is not
affected by ceramide [160]. On the other hand, other reports
showed that treatment of cortical astrocytes with palmitate [167]
or C2-ceramide [168,169] causes apoptosis, which is mediated
by an increase in ceramide generated de novo. Activation of
Raf-1/Erk [167] and release of mitochondrial cytochrome c
[169] are involved in ceramide-induced apoptosis.
One well-characterized role of ceramide in astrocytes is in
proliferation. Astrocyte proliferation is essential during devel-
opment of the nervous system and is the main process activated
during astrogliosis in response to ischemia, brain injury and in
neurodegenerative diseases. In quiescent primary astrocytes
induction of proliferation with basic Fibroblast Growth Factor
(bFGF) causes a rapid and transient decrease in ceramide
content, and exogenous ceramide counteracts the proliferating
actions of bFGF by decreasing Erk 1/2 activation [170]. The
decrease in ceramide levels upon bFGF treatment is due to
stimulation of SM synthase [171]. Exogenously added S1P also
causes astrocyte proliferation in the absence of bFGF by a
mechanism mediated by S1P receptors [172]. Importantly,
bFGF induce astrocytes to release S1P but not SphK. Moreover,
ceramide, which has antiproliferative effects in astrocytes
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consistent with the presence of the S1P/ceramide “rheostat” in
astrocytes.
6. Ceramide and ceramide metabolites in
neurodegenerative diseases
The role of sphingolipids in the development and progres-
sion of several neurological diseases, in particular lipid storage
diseases, is well recognized. In addition, in the past few years
increasing evidence has pointed out the relevance of simpler
sphingolipids like ceramide in other neurological dysfunctions,
particularly dementias.
6.1. Alzheimer’s disease
Alzheimer's disease (AD) is a devastating progressive
neurodegenerative disorder with characteristic clinical and
pathological features. Since age is a major risk factor for AD,
the incidence of this disease is rising as people continue to live
longer, especially in developed countries. The number of
individuals who have AD is projected to almost double by 2025
in North America underscoring the importance of under-
standing the molecular mechanisms that lead to the disease
development.
Accumulation of Aβ leads to the progression of character-
istic morphological features of AD namely intraneuronal
neurofibrillary tangles, extracellular amyloid plaques (neuritic
or senile plaques), and cerebrovascular angiopathies [173,174].
A link between AD and lipid homeostasis has been provided
initially by the finding that the E4 allele of apolipoprotein E
(apoE) associates with a higher risk of developing both late
familial [175,176] and sporadic AD [177] as well as certain
early-onset forms of the disease [178]. Later studies haveFig. 2. Amyloidogenic and non-amyloidogenic processing of APP. The transmembra
domains and by β-secretase (BACE) in lipid rafts domains generating the correspond
and sAPPβ respectively. α-cleavage of APP precludes the formation of Aß. γ-secre
activity of. In both pathways γ-secretase releases APP intracellular domain (AICD)demonstrated significant alterations of several lipids (e.g.,
ceramide, gangliosides, cholesterol and sulfatide) in AD.
Extensive evidence supports an important role of cholesterol
in the development and possibly progression of AD (reviewed
by [179,180]. The role of sphingolipids is also emerging.
Ceramide elevation in the brain is evident at an early stage in
AD patients [181,182]. This substantial elevation of ceramide
might result from degradation of sulfatide, which is reduced in
brain grey and white matter and in cerebrospinal fluid of
patients with AD [181,183]. Indeed, in AD brains the profile of
molecular species of ceramide correlates more closely with
sulfatide molecular species than with SM molecular species
[181]. Sulfatide mass content seem to be modulated by apoE
[184,185] but the reasons for the pronounced deficiency of
sulfatide in AD brain are still unknown. Nevertheless, sulfatide
deficiency has been suggested as a potentially useful biomarker
of AD [184]. On the other hand, studies by Mattson and
collaborators suggested that the increase of ceramide in ADmay
result, at least in part, from membrane-associated oxidative
stress and might be accompanied by a decrease in SM [182].
6.1.1. Modulation of APP cleavage and Aβ production by lipids
Aβ is a peptide derived from intramembrane sequential
cleavage of the amyloid precursor protein (APP) by β-site APP
cleaving enzyme 1 (BACE1) and γ-secretase (Fig. 2) [186]. The
amyloidogenic pathway of APP clevage occurs normally in all
cells rendering two main Aβ peptides of 40 and 42 aminoacids
respectively (Aβ40 and Aβ42). Under physiological conditions
however, APP is predominantly cleaved by α-secretase,
resulting in the secretion of soluble APP (sAPPα) and
precluding excessive Aβ formation. The proteolytic processing
of APP takes place predominantly in post-Golgi secretory and
endocytic compartments and at the plasma membrane
[187,188]. The amyloidogenic processing of APP seems tone protein APP is cleaved by α-secretases in cholesterol- and sphingolipid-poor
ent C-terminal fragments (CTFs) C83 and C99 and the large ectomains sAPPα
tase cleavage of C83 results in the release of P3. Aβ is the result of γ-secretase
, which may be involved in nuclear signaling.
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cleavage takes place in non-raft regions of the membranes
[189].
The involvement of rafts in Aβ production is supported by
evidence that BACE1 [190,191], γ-secretase [192–195] and
APP [190,196,197] localize at least in part, to lipid rafts.
Sphingolipids and cholesterol are major components of lipid
rafts and changes in cellular sphingolipids or cholesterol levels
regulate Aβ generation. The correlation between cellular
cholesterol and Aβ production is still controversial. Several
studies indicated that cholesterol depletion leads to decreased
Aβ production [190,198,199] and stimulation of the non-
amyloidogenic cleavage pathway [200]. Conversely, at least
one report showed increased Aβ generation upon moderate
reduction of cellular cholesterol levels [201]. These discrepan-
cies have been reconciled in a model that takes in consideration
the impact of different levels of cholesterol on the structure of
lipid rafts [202].
Similarly, the precise role of sphingolipids in APP proces-
sing and Aβ production is contentious. The discrepancy in the
data obtained by different research groups might result from the
use of different approaches to regulate sphingolipid levels. In
cultured cells expressing APP, exogenous addition of C6-
ceramide or N-SMase increases Aß generation by regulating β-
cleavage through BACE1 stabilization but without affecting γ-
cleavage of APP [203]. Elevated Aß secretion is accompanied
by an increase in α- and β-C-terminal fragments (CTF)
production but with no change in APP expression or maturation.
Accordingly, treatment with FB1 causes reduction of ceramide
levels and a decrease in Aβ as well as in α- and β-CTF
generation [203]. Interestingly the authors found that the
reduction of SM that results from treatment with N-SMase or
treatment with FB1 cause similar decrease in cholesterol
clustering into cholesterol-rich domains, however only when
decreased cholesterol in lipid rafts is accompanied by reduced
ceramide levels (FB1 treatment) it resulted in decreased Aß
generation. Conversely, decreased cholesterol in lipid rafts in
the presence of elevated ceramide (treatment with nSMase)
leads to increased Aß production. Although these results
suggest that ceramide could be creating “lipid raft-like patches”
where BACE1 might localize, the authors claim that, at list C6-
ceramide, does not affect the overall distribution of BACE
among microdomains. Instead they attribute their results to a
more direct effect of ceramide on BACE1 activity by post-
translational stabilization of BACE1 [203]. More recently, the
pool of ceramide involved in BACE1 stabilization has been
suggested to derive from p75NTR-activated N-SMase, although
direct activation of N-SMase has not been measured in those
studies [204].
Work by Sawamura and collaborators demonstrated that
reduction of cellular sphingolipid levels by inhibition of SPT
(treatment with myriocin or use of a mutant defective in the
LCB1 subunit of palmitoyltransferase) results in increased
secretion of sAPPα but not sAPPβ, and increase production of
Aβ42 [205]. Since with this experimental approach the levels of
all sphingolipids, including ceramide are reduced, their results
contradict the findings of Puglielli et al. [203]. Although someof the discrepancies could be attributed to the accumulation of
sphinganine (and PKC inhibition) in cells treated with FB1
[205], the inconsistency in Aβ production remains unexplained.
In addition, cells treated with the GlcCer synthase inhibitor
PDMP showed reduced secretion of both sAPP and Aβ [206].
The authors inferred that reduced Aβ secretion depends on the
decrease of glycosphingolipids and not on ceramide accumula-
tion since exogenous C6-ceramide caused no change in sAPP
secretion in their model. They interpreted that decreased
generation of Aβ upon cellular glycosphingolipid depletion
might result from reduced access of BACE1 to APP in the
endocytic compartments due to reduction of APP maturation in
the secretory pathway, and reduction of APP movement to the
plasma membrane. This study [206] therefore suggests that
glycosphingolipids might be implicated in the forward transport
of APP in the secretory pathway.
In spite of the great effort dedicated to understand the role of
lipids in the regulation of Aβ production during disease, much
less attention was paid to the physiological functions of APP
and Aβ. New exciting evidence suggests that APP processing
and Aβ production regulates cholesterol and SM metabolism
[207]. Aβ42, at physiological concentrations, directly activates
N-SMase and causes a decrease in SM levels, while Aβ40
reduces de novo cholesterol synthesis by inhibiting the key
enzyme of the biosynthetic pathway, hydroxy-methyl glutaryl
coenzyme-A reductase (HMG-CoA reductase). Interestingly,
this work suggests that production of ROS that had previously
been involved in many of the effects of Aβ (see below) is not
responsible for Aβ-induced N-SMase activation at lower
(physiological) levels of Aβ [207].
6.1.2. Ceramide as a second-messenger in the cytotoxic effects
of Aβ
Several lines of evidence linked Aß with neuronal death
[208]. Aβ causes death of neurons by mechanisms dependent
and independent of caspases [209–211]. We have recently
demonstrated that in neurons exposed to Aβ exclusively in the
axons neurons die by a process of caspase-mediated apoptosis,
which is secondary to caspase-independent axonal degeneration
[212].
The molecular events that lead to Aβ-induced neuronal
degeneration and death are under debate. Some studies suggest
that a direct effect of Aβ on neurons is required. Interaction of
Aβ with RAGE [213], α-7AChR [214], and p75NTR [215] has
been linked to AD. Other studies support the notion that the
effect of Aβ is indirect, activating microglia and causing
inflammation [216]. There is sufficient evidence that inflam-
matory mechanisms induced by TNF-α and other cytokines are
involved in AD. In addition, induction of membrane-associated
oxidative stress has been identified as a key mechanism in Aβ-
induced toxicity. Previous studies demonstrated that Aβ-
induced cell death is mediated by a mechanism involving
lipid peroxidation and oxidative stress [217,218] and that there
is cross-talk between the oxidation-stress system and the SM/
Cer pathway.
Ceramide has also been identified as a possible second
messenger in Aβ-induced death. Evidence from different
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[38,39,44,45,182] or intracerebral administration of Aβ to rats
[40] causes ceramide elevation and that the apoptotic effects
of Aβ are mimicked by exogenous short-chain ceramides
[38,42,45].
The origin of the ceramide pool generated upon Aβ
treatment is still unclear. Aβ-induced activation of N-SMase
has been demonstrated in human primary neurons, oligoden-
drocytes and cerebral endothelial cells [38,44,45]. Unfortu-
nately, the Aβ peptide used for most of the studies in
oligodendrocytes and endothelial cells was Aβ25–35, which
does not exist in vivo. Although Aβ25–35 and Aβ40 showed
similar potency in the induction of apoptosis [219,220], this
cannot be interpreted as an indication that the two peptides
cause apoptosis by the same mechanisms. Hence, direct
demonstration of N-SMase activation by the relevant peptide
Aβ42 or Aβ40 in oligodendrocytes is still missing. This is
particularly relevant in view of evidence discussed above
showing that Aβ42 but not Aβ40 activates N-SMase at
physiological concentrations [207]. Other studies in vivo
implicating N-SMase in the development of AD suffer of
poor identification of the Aβ peptide used [40]. In addition,
studies in hippocampal neurons that suggest that SM is the
source of ceramide generation were performed with the relevant
peptide Aβ42 but did not examine SMase activity [182].
Moreover, in this last work, data derived from experiments
using the SPT inhibitor myriocin are difficult to interpret.
Although the authors claim that hippocampal neurons were
depleted of SM upon treatment with myriocin, the actual levels
of SM were only slightly decreased; and ceramide levels were
unaffected or conversely, Cer C24:0 was significantly increased
in myoricin-treated neurons compared to untreated neurons.
Nevertheless, myriocin was able to prevent the increase in
ceramide triggered by Aβ and partially protected neurons from
Aβ-induced apoptosis, which suggests that under those
experimental conditions the pool of ceramide involved in Aβ
actions derives more likely from de novo pathway of ceramide
synthesis [182].
The mechanisms by which Aβ causes N-SMase activation
and ceramide accumulation seem to be redox-sensitive and to
entail activation of NADPH oxidase and/or regulation of
glutathione metabolism [38,44]. In support for the involvement
of oxidative stress, in hippocampal neurons treated with Aβ,
ceramide elevation is accompanied by an increase in the
peroxidation product 4-hydroxynonenal (HNE) and is pre-
vented by the antioxidant α-tocopherol [182]. Unexpectedly
though, treatment with myriocin completely abolishes the
increase in 4HNE induced by Aβ, which would suggest that
lipid peroxidation is secondary to Aβ-induced ceramide
elevation or alternatively that myriocin has unrelated, non-
specific effects in this system.
In conclusion, there is growing and exciting evidence that a
reciprocal regulation between lipids (sphingolipids and choles-
terol) and Aβ exists. Sphingolipids have emerged as significant
regulators of Aβ production; and alteration of sphingolipid
metabolism might be associated with the development of
sporadic AD. More studies in vivo are required to understandthe molecular details of the role of sphingolipids in Aß
generation and toxicity.
6.2. HIV-associated dementia
In the late stages of acquired immunodeficiency syndrome
(AIDS) 20–30% of the patients present severe neurological
disabilities identified as Human Immunodeficiency virus type 1
(HIV-1)-associated dementia (HAD) [221]. Histopathology of
brains from HAD patients demonstrate gliosis, abnormalities of
dendritic processes and neuronal apoptosis [222]. The exact
mechanisms by which the virus causes apoptosis are still
unknown. HIV-1 infects susceptible cells by fusion of the viral
membrane with the cell plasma membrane. This process is
mediated by the interaction of the HIV-1 envelope glycoprotein
gp120 with CD4 and the co-receptors CXC chemokine receptor
4 and 5 (CXCR4 and CCR5) present on the host cell surface
[223]. Several lines of evidence indicate that these interactions
occur at distinct domains on the target-cell membrane [224] and
that disruption of domain structure by cholesterol depletion
causes inhibition of HIV infection [225].
Recent evidence indicates that the HIV coat protein gp120,
which has been implicated in the pathogenesis of HAD,
causes neuronal apoptosis. gp120 induces the activation of
SMase (primarily N-SMase) and generation of ceramide.
SMase activation is triggered by coupling of gp120 to the
CXCR4 and the induction of NADPH oxidase-mediated pro-
duction of superoxide radicals [37]. Consistently, recent
finding by Haughey and colleagues have shown that over-
production of ceramide may be involved in neuronal death in
HAD patients [226]. Sphingolipid deregulation is more pro-
nounced in HAD patients with an apoE4 genotype, who have
worse prognoses [227], however the link between apoE
genotype and the altered sphingolipid metabolism is unclear
and deserves further study.
Contrary to the notion that increased ceramide is detrimental
for HIV-related disease it was demonstrated that elevation of
ceramide by pharmacological manipulation of the ceramide
synthetic pathway, by treatment with SMase, or by direct
addition of long-chain ceramides makes cells resistant to HIV
infection due to inhibition of membrane fusion [228]. As a
consequence the biosynthetic pathway of ceramide has been
proposed as a possible novel target for HIV treatment. Further
studies are required to reconcile the pros and cons of ceramide
increase in HAD.
7. Conclusions
In summary, it is clear that simple sphingolipids like
ceramide and S1P play pivotal roles in life and death of cells
from the nervous system. The cellular fate is intrinsic to the
neuronal type and a same molecular target can be regulated by
the same sphingolipid with opposing results. Nevertheless some
general mechanisms exist in the action of ceramide and its
metabolites in different neuronal types. In particular, the
mechanisms involved in the induction of neuronal apoptosis
are shared by many neuronal types. On the other hand, more
2010 E.I. Posse de Chaves / Biochimica et Biophysica Acta 1758 (2006) 1995–2015specific molecular pathways are activated in systems in which
sphingolipids induce cell survival. Although the reasons for
differential mechanisms to be activated in certain neuronal types
and not in others are still obscure, it is obvious that we cannot
attribute “a priori” a certain cellular outcome to ceramide or S1P
treatment.
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